Targeting ANO1 inhibition can enhance HNSCC sensitivity to chemo-radiotherapy, providing a novel precision treatment strategy for high-risk patients and offering a potential therapeutic target for personalized therapy, such as combined PI3K/EGFR inhibition (197). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.